Search Results - "Neubauer, M. A."

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study by Rothenberg, M. L., Benedetti, J. K., Macdonald, J. S., Seay, T. E., Neubauer, M. A., George, C. S., Tanaka, M. S., Giguere, J. K., Pruitt, B. T., Abbruzzese, J. L.

“…Background: Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)…”
Get full text

Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation by Neubauer, M A, Benyunes, M C, Thompson, J A, Bensinger, W I, Lindgren, C G, Buckner, C D, Fefer, A

“…Immunotherapy with interleukin-2 (IL-2) early after peripheral blood stem cell transplantation (PBSCT) is being considered as a potential way to eradicate…”
Get more information

Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma by THOMPSON, J. A, BIANCO, J. A, BENYUNES, M. C, NEUBAUER, M. A, SLATTERY, J. T, FEFER, A

“…The dose of interleukin 2 (IL-2) which can be administered to cancer patients is limited largely by a capillary leak syndrome. Pentoxifylline (PTX) is a…”
Get full text

A clinical pathways project to promote evidence-based medicine in a large community oncology practice by Neubauer, M. A.

“…Abstract only 6597 Background: Medical oncology therapy tends to vary widely due to a large number of drug choices and a wide array of reference sources for…”
Get full text

Randomized, double-blind, placebo-controlled phase II study of erlotinib with and without entinostat, a class 1 isoform selective histone deacetylase inhibitor (HDAC), in patients with advanced non-small cell lung cancer (NSCLC; ENCORE-401) by Jotte, R., Witta, S. E., Neubauer, M. A., Spira, A. I., Konduri, K.

“…Abstract only…”
Get full text

Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network by Neubauer, M. A., Espirito, J. L., Clayton, M., Patt, D. A.

“…Abstract only…”
Get full text

The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN 01-24/USO-023 by Jayaram, N. H., Neubauer, M. A., Johnson, C. S., Breen, T., Williams, C. E., Hanna, N. H.

“…Abstract only…”
Get full text

Disseminated histoplasmosis in patients with AIDS by Neubauer, M A, Bodensteiner, D C

“…Disseminated histoplasmosis (DH) is recognized as an opportunistic infection in patients with the human immunodeficiency virus (HIV), especially in regions…”
Get more information

Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community by Patt, D. A., Espirito, J. L., Turnwald, B., Hoverman, J. R., Neubauer, M. A., Busby, L. T., Brooks, B. D., Kolodziej, M. A., Anderson, R. W., Beveridge, R. A.

“…Abstract only 213 Background: Selection of adjuvant breast cancer (BC) therapy varies based on patient risk factors. Choice of chemotherapy (CT), schedule,…”
Get full text

Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): Outcomes from a community oncology network by Neubauer, M. A., Garey, J. S., Nelson, G. C., Patt, D. A., Cartwright, T. H., Hoverman, J. R., Busby, L. T., Brooks, B. D., Sitarik, M. A., Kolodziej, M. A., Anderson, R. W., Beveridge, R. A.

“…Abstract only…”
Get full text

Understanding male breast cancer in the community setting by Ginsburg, A. L., Patt, D. A., Flinn, J., Espirito, J. L., Neubauer, M. A., Cartwright, T. H., Hoverman, J. R., Busby, L. T., Brooks, B. D., Kolodziej, M. A., Sitarik, M. A., Anderson, R. W., Beveridge, R. A.

“…Abstract only…”
Get full text

Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status by Cohn, A. L., Smith, D. A., Neubauer, M. A., Houston, G., Khandelwal, P., Wiggans, R. G., Zhang, K., Yassine, M.

“…Abstract only 4067^ Background: Pmab, a fully human antibody to the epidermal growth factor receptor (EGFR), is indicated as monotherapy for treatment of…”
Get full text

Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC) by Weissman, C. H., Reynolds, C. H., Neubauer, M. A., Steinberg, I., Asmar, L.

“…Abstract only…”
Get full text

Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community by Patt, D. A., Espirito, J. L., Turnwald, B., Hoverman, J. R., Neubauer, M. A., Cartwright, T. H., Brooks, B. D., Busby, L. T., Sitarik, M. A., Kolodziej, M. A., Ginsburg, A. L., Sheth, S., Garey, J. S., Clayton, M., Nelson, G. C., Anderson, R. W., Beveridge, R. A.

“…Abstract only…”
Get full text

Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology by Wickline, Samuel A, Neubauer, Anne M, Winter, Patrick, Caruthers, Shelton, Lanza, Gregory

“…The role of nanotechnology in cardiovascular diagnosis is expanding rapidly. The goal of this brief review is to illustrate selected examples of nanosystems…”
Get full text

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023—Updated results by Mina, L. A., Neubauer, M. A., Ansari, R. H., Govindan, R., Einhorn, L. H., Fisher, W., Bruetman, D., Chowhan, N. M., Johnson, C., Hanna, N. H.

“…Abstract only…”
Get full text

Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI by Cohn, A. L., Smith, D. A., Neubauer, M. A., Houston, G., Khandelwal, P., Wiggans, R. G., Suzuki, S., Yassine, M., Deeter, R., Sikorski, R.

“…Abstract only…”
Get full text

Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial by Raju, R. N., Neubauer, M. A., Smith, D. A., Richards, D. A., Asmar, L., Cunneen, J. L., Chen, R., Tai, D. F., Obasaju, C. K., Socinski, M. A.

“…Abstract only 7716 Background: Pts with relapsed SCLC have a poor prognosis and few effective treatment options. P is a novel multitargeted antifolate that is…”
Get full text

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium by Koselke, PharmD, BCOP, Elizabeth, C. Kaspin-Powell, PhD, Lisa, Hough, PharmD, BCOP, Shannon, Howell, PharmD, BCOP, Joshua, J. Robert, MD, Nicholas, A. Neubauer, MD, Marcus, A. Bullock, DNP, MPH, RN, OCN®, CCRP, Susie, M. Walberg, MPH, Jennifer, Rammage, PharmD, MS, BCOP, Melissa, E. Butrynksi, MD, James, Hakimian, MD, David, M. Jotte, MD, PhD, Robert, W. Meshad, MD, Michael, Ali, MD, Kashif, Michael Waterhouse, MD, MPH, David, L. Coleman, MD, FACOG, FACS, Robert, Colleen Evangelist, MD, Makenzi

“…Introduction: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium™ (MYLUNG) clinical trial platform aims to…”
Get full text

super(19)F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons by Partlow, K C, Chen, J, Brant, JA, Neubauer, A M, Meyerrose, TE, Creer, M H, Nolta, JA, Caruthers, S D, Lanza, G M, Wickline, SA

“…MRI has been employed to elucidate the migratory behavior of stem/progenitor cells noninvasively in vivo with traditional proton ( super(1)H) imaging of iron…”
Get full text